---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086030"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T19:26:18.779759+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook

## Summary
- GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.
- Total sales $15,035M (+3% YoY); excluding LAGEVRIO, sales grew 11% (+14% ex-FX).
- KEYTRUDA sales $6,271M (+19% YoY); GARDASIL/GARDASIL 9 sales $2,458M (+47% YoY).
- LAGEVRIO sales fell 83% to $203M; non-GAAP EPS loss of $2.06 vs. $1.87 gain a year ago.
- FY 2023 sales outlook raised to $58.6-59.6B; non-GAAP EPS outlook $2.95-3.05 (includes -$4.53/share one-time charges).

## SEC filing metadata
- accession: 0001104659-23-086030
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/0001104659-23-086030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/tm2322190d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086030
- JSON: https://secwatch.observer/filing/0001104659-23-086030.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086030.txt

## Key facts
- Earnings Releases
  Merck & Co., Inc. reported the second quarter of 2023 results: revenue $15.0 Billion, net income $(5,975) million, EPS ($2.35) per share. Guidance raised.
  - Period: the second quarter of 2023
  - Revenue: $15.0 Billion
  - Net income: $(5,975) million
  - EPS: ($2.35) per share
  - Guidance: raised
  - Result: reported results
  source text: Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% ○ GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 53% ○ LAGEVRIO Sales Declined 83% to $203 Million; Excluding the Impact of Foreign Exchange, Sales Declined 82% - GAAP Loss per Share Was $2.35; Non-GAAP Loss per Share Was $2.06; GAAP and Non-GAAP Loss per Share Include a Charge of $4.02 per Share for the Acquisition of Prometheus - Presented Compelling Data in Earlier Stages of Cancer at 2023 ASCO Annual Meeting, Including: o Positive Phase 3 Results From KEYNOTE-671 Trial o Promising New Data From Phase 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/0001104659-23-086030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.